findmyKOL
Clinical trialNCT00561834CompletedPhase 1Interventional

Ranibizumab Therapy for Non-arteritic Ischemic Optic Neuropathy

SponsorUniversity of Colorado, DenverEnrollment2Nonarteritic Anterior Ischemic Optic Neuropathy
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of this study is to explore the safety and efficacy of ranibizumab to treat non-arteritic ischemic optic neuropathy based on clinical and anatomical findings.

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

  • Naresh Mandava, MD

    Rocky Mountain Lions Eye Institute, University of Colorado Health Sciences Center

    Principal Investigator

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Rocky Mountain Lions Eye Institute

    Aurora, Colorado, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
30 Nov 2007
Primary completion
30 Apr 2009
Completion
30 Apr 2009
Last update posted
30 Sept 2016
Registered enrollment
2
Registry id
NCT00561834

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.